Antidepressant drugs that work in hours instead of weeks could be on the market within three years, researchers say.
"We're getting closer and closer to having really, truly next-generation treatments that are better and quicker than existing ones," says Dr. Carlos Zarate, a researcher at the National Institute of Mental Health.
The new drugs are based on the anesthetic ketamine, which is also a popular club drug known as Special K. Unlike current antidepressants, which can take weeks to work, ketamine-like drugs have an immediate effect. They also have helped people with depression who didn't respond to other medications.
The drug that is furthest along is esketamine, a chemical variant of ketamine that has been designated a potential breakthrough by the Food and Drug Administration. Esketamine is poised to begin Phase 3 trials, and the drug's maker, Johnson & Johnson, plans to seek FDA approval in 2018.
Another ketamine-like drug on the horizon is rapastinel. It has completed Phase 2 studies, which showed "rapid, substantial, and sustained reductions in depressive symptoms," according to the drug's maker, Naurex.
"I think it's highly probable that we'll see some version of one of these treatments being approved in the relatively near future," says Dr. Gerard Sanacora, director of the Yale Depression Research Program. "In my mind it is the most exciting development in mood disorder treatment in the last 50 years."
Sanacora has done consulting work for both Naurex and Johnson & Johnson. He is also an investigator for a study in which esketamine will be given to suicidal patients.
The new drugs come nearly a decade after Zarate and other researchers from the National Institutes of Health published a study showing that ketamine helped most people with major depression in less than two hours. "When we saw the first initial responses you say, wow, this will definitely revolutionize our treatments for mental illness," Zarate says.
Since then, many other studies have confirmed that ketamine usually works even when other drugs have failed. "At this point I think it's incontrovertible that the drug has clear, robust rapid antidepressant effect," Sanacora says. Studies suggest that effect usually lasts for a week or so.
But ketamine itself has shortcomings. It can cause hallucinations, and it's a drug that is frequently abused.
Also, from the perspective of drug companies, ketamine is problematic because it is already available as an inexpensive generic drug. So companies including Naurex and Johnson & Johnson began searching for compounds they could patent that would have a similar effect in the brain.
If esketamine and repastinel reach the market, they could be blockbuster sellers. Johnson & Johnson included esketamine on a list of drugs with potential annual sales of more than $1 billion.
In the meantime, many psychiatrists are already prescribing ketamine to severely depressed patients who haven't been helped by other drugs, even though ketamine hasn't been approved by the FDA for that purpose. This sort of "off-label" prescribing is common in psychiatry, Zarate says.
"I don't think it's necessarily irresponsible," says Sanacora, who has prescribed off-label ketamine to some of his own patients. But it's important that patients who get the drug understand that it's still experimental and are warned of potential risks. He also recommends that patients who want to try ketamine enter a clinical trial.
One looming question about all the ketamine-like drugs is whether they will be safe and effective after months or years of use. "Maintaining is going to be key," Zarate says.
DAVID GREENE, HOST:
Today in Your Health - some promising new medical treatments. We begin with an update on treating depression that involves a club drug known as Special K. NPR's Jon Hamilton reports.
JON HAMILTON, BYLINE: Special K is the street name for an anesthetic called ketamine. In high doses, it can produce out-of-body experiences. More than a decade ago, researchers realized ketamine had another effect - it could relieve major depression within an hour or two. Gerard Sanacora, who directs the Yale Depression Research Program, says that was a revelation.
GERARD SANACORA: This had the potential to truly change the way we're treating depression. Both in the fact that it has a very rapid onset of effect and also in the fact that it seemed to be working in patients where the standard antidepressants had failed to produce much benefit.
HAMILTON: But Sanacora says ketamine, itself, has some drawbacks.
SANACORA: Ketamine is a known drug of abuse. It's also a drug that has some fairly significant effects on blood pressure and heart rate.
HAMILTON: So drug companies are testing similar compounds with fewer side effects. Two of the most promising are called esketamine and rapastinel. Each is headed for the final stage of testing before consideration by the Food and Drug Administration. Sanacora, who consults for the makers of both drugs, says he's optimistic.
SANACORA: Some version of one of these drugs is likely to make it to the clinical market within a relatively short period of time.
HAMILTON: Johnson & Johnson, which makes esketamine, plans to seek FDA approval in 2018. The company says potential sales could exceed $1 billion a year. Jon Hamilton, NPR News. Transcript provided by NPR, Copyright NPR.